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Summary
 
The role of T helper type 1 (Th1) and Th2 cells in tumor immunity was investigated using Th
cells induced from ovalbumin (OVA)-specific T cell receptor transgenic mice. Although Th1
cells exhibited stronger cytotoxicity than Th2 cells, both cell types completely eradicated tu-
mors when transferred into mice bearing A20 tumor cells transfected with the OVA gene
(A20-OVA). Th1 cells eradicated the tumor mass by inducing cellular immunity, whereas Th2
cells destroyed the tumor by inducing tumor necrosis. Both Th1 and Th2 cells required CD8
 
1
 
T cells to eliminate tumors, and neither of these cells were able to completely eliminate A20-
OVA tumors from T and B cell–deficient RAG2
 
2
 
/
 
2
 
 mice. Mice cured from tumors by Th1
and Th2 cell therapy rejected A20-OVA upon rechallenge, but CD8
 
1
 
 cytotoxic T lympho-
cytes were induced only from spleen cells prepared from cured mice by Th1 cell therapy.
Moreover, we demonstrated that Th1 and Th2 cells used distinct adhesion mechanisms during
tumor eradication: the leukocyte function-associated antigen (LFA)-1–dependent cell–cell ad-
hesion step was essential for Th1 cell therapy, but not for Th2 cell therapy. These findings
demonstrated for the first time the distinct role of antigen-specific Th1 and Th2 cells during
eradication of established tumors in vivo.
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T
 
he ultimate goal of tumor immunotherapy is to induce
tumor-specific T cell–mediated immunity that can
block the growth and metastasis of malignant tumor cells in
a tumor-bearing host (1). However, because of low immu-
nogenicity and strong immunosuppression, this goal has
been difficult to achieve (2, 3). To overcome this problem,
it is essential to activate helper function at the tumor site
(4). Many strategies have been devised to introduce local
help: (a) introduction of cytokines or cytokine genes into
the host (5, 6); (b) adoptive transfer of antigen-specific or
nonspecific CD4
 
1
 
 Th cells into tumor-bearing mice (7–9);
(c) activation of cytokine production in vivo by immuno-
potentiators (10, 11); (d) dendritic cell–based vaccine ther-
apy (12, 13); and (e) targeting of MHC class II–binding su-
perantigens into the tumor site (14, 15).
CD4
 
1
 
 Th cells can be subdivided into Th1 and Th2
cells. The balance of these cells (Th1/Th2 balance) has
been shown to be critically important in various immune
responses, including antitumor immune responses (16).
Since Th1 cells producing IFN-
 
g
 
 and IL-2 are essential for
the induction of cellular immunity, whereas Th2 cells pro-
ducing IL-4, IL-5, and IL-10 play a key role in humoral
immunity, it seems likely that the activation of Th1-dominant
local help could facilitate the induction of antitumor im-
munity (17). Indeed, IL-12 has been demonstrated to be
effective in inducing antitumor immunity in vivo through
the activation of Th1 immunity (17–19). However, both
Th1-derived cytokines (IL-2, IFN-
 
g
 
) and Th2-derived cyto-
kines (IL-4, IL-6, IL-10) have been demonstrated to be
useful for cancer gene therapy (20–23). Moreover, tumor-
specific Th2 clones were demonstrated to exhibit a strong
antitumor activity in vivo (24). These controversial results
have made it difficult to understand which cells, Th1 or
Th2, are critical for antitumor immune responses.
To understand the precise role of Th1 and Th2 cells in
tumor eradication, it is necessary to prepare a large number
of monoclonal Th1 and Th2 cells from the same naive Th
precursor cells in short-term cultures. Moreover, it is essen-
tial to perform these experiments with Th1 and Th2 cells
that are specific for the same tumor-rejection antigen
(TRA).
 
1
 
 These requirements have been hard to achieve
 
1
 
Abbreviations used in this paper:
 
 ICAM, intercellular adhesion molecule;
OVA-pep, I-A
 
d
 
–binding OVA
 
323–339
 
 peptide; RAG, recombination acti-
vating gene; Tg, transgenic; TRA, tumor-rejection antigen. 
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because of difficulties in inducing large numbers of Th1
and Th2 cells that recognize the same tumor antigen in
short-term cultures. Using long-term cultures it may be
possible to generate Th1 and Th2 clones that recognize the
same tumor antigen, but the properties of these clones may
not necessarily reflect the in vivo situation.
To overcome this problem, we induced Th1 and Th2
cells from transgenic (Tg) mice expressing TCR 
 
a
 
/
 
b
 
 chain
genes, derived from a chicken OVA–specific I-A
 
d
 
–restricted
CD4
 
1
 
 Th clone (25). We used these cells in conjunction
with I-A
 
d
 
–positive tumor cells expressing OVA antigen
(A20-OVA), as a model TRA in order to examine the role
of OVA-specific Th1 and Th2 cells in tumor eradication in
vivo. The in vivo antitumor activity of Th1 and Th2 cells
was compared by adoptive cell transfer into mice bearing
an established A20-OVA tumor mass. Using this novel
adoptive tumor immunotherapy model, we demonstrated
for the first time the distinct role of antigen-specific Th1
and Th2 cells for tumor eradication in vivo.
 
Materials and Methods
 
Animals.
 
BALB/c mice were obtained from Charles River
Japan. BALB/c background recombination activating gene
(RAG)2
 
2
 
/
 
2
 
 mice were donated by Dr. M. Ito (Central Institute
for Experimental Animals, Kanagawa, Japan). OVA
 
323–339
 
-specific
I-A
 
d
 
–restricted TCR-Tg mice (DO11.10) maintained on the
BALB/c background were donated by Dr. K.M. Murphy (Wash-
ington University School of Medicine, St. Louis, MO [25]). All
the mice were female and were used at 5–6 wk of age.
 
Cytokines, mAbs, and Antigens.
 
IL-12 was donated by Genet-
ics Institute. Anti–IL-12 mAbs (C15.1 and C15.6) were a gift
from Dr. G. Trinchieri (Wistar Institute of Anatomy and Biol-
ogy, Philadelphia, PA). PMA, brefeldin A, recombinant murine
IL-4, and antiasialo GM1 Ab were purchased from Wako Pure
Chemical Industries, Ltd. Anti–IL-4 mAb (11B11) was purchased
from American Type Culture Collection. PE–anti-CD4 mAb,
peridinine chlorophyll protein (PerCP)–anti-CD4 mAb, FITC–
anti-CD45RB mAb, FITC–anti-CD8 mAb, purified anti-CD3
mAb, purified anti–very late antigen (VLA)-4, purified anti–
intercellular adhesion molecule (ICAM)-1 mAb, and recombi-
nant mouse IFN-
 
g
 
 and anti–IFN-
 
g
 
 mAb (R4-6A2) were pur-
chased from PharMingen. Anti–LFA-1 mAb was produced by
our established KBA hybridoma clone (26). OVA
 
323–339
 
 peptide
was supplied by Dr. H. Tashiro (Fujiya Co. Ltd., Hadano, Japan).
 
Generation of Th1 and Th2 Cells.
 
CD4
 
1
 
CD45RB
 
1
 
 naive T
cells were isolated from nylon-passed spleen cells from DO11.10
TCR-Tg mice using cell sorting (FACS Vantage™; Becton
Dickinson) as described previously (27). Purified CD4
 
1
 
CD45RB
 
1
 
cells were stimulated with 10 
 
m
 
g/ml OVA
 
323–339 
 
peptide in the
presence of mitomycin C–treated BALB/c spleen cells, 20 U/ml
IL-12, 1 ng/ml IFN-
 
g
 
, 50 
 
m
 
g/ml anti–IL-4 mAb, and 20 U/ml
IL-2 for Th1 development. Th2 cells were induced from the
same naive Th cells in the presence of 1 ng/ml IL-4, 50 
 
m
 
g/ml
anti–IFN-
 
g
 
 mAb, 50 
 
m
 
g/ml anti–IL-12 mAbs, and 20 U/ml IL-2.
At 48 h, cells were restimulated with OVA
 
323–339
 
 under the same
conditions, and used at 9–12 d of culture.
 
Induction of LFA-1/ICAM-1–dependent Homotypic Aggregation.
 
Th1 or Th2 cells (2 
 
3 
 
10
 
6
 
 cells/well) were cultured in 12-well
plates and stimulated with 2 
 
m
 
g/ml of anti-CD3 mAb or 20 ng/
ml of PMA for 1–2 h. The ability of Th1 or Th2 cells to form
 
homotypic aggregation was determined by counting the number
of cell aggregates under the microscope as described previously
(28). The blocking effect of mAbs was determined by adding 50
 
m
 
g/ml of each mAb into the culture.
 
Cytokine Activity.
 
IFN-
 
g
 
 or IL-4 activities of culture super-
natants were measured using ELISA kits (Nycomed Amersham
plc). The IFN-
 
g
 
 activity was determined using Biotrak IFN-
 
g
 
ELISA kits (RPN2717), and IL-4 activity was determined using
Biotrak IL-4 ELISA kits (RPN2712). The mean of triplicate sam-
ples was calculated.
 
Intracellular Cytokine Expression.
 
For the detection of cyto-
plasmic cytokine expression, cells stimulated with immobilized
anti-CD3 mAb for 6 h in the presence of brefeldin A were first
stained with PerCP–anti-CD4 mAb, fixed with 4% paraformal-
dehyde, and treated with permeabilizing solution (50 mM NaCl,
5 mM EDTA, 0.02% NaN
 
3
 
, 0.5% Triton X-100, pH 7.5), then
the fixed cells were stained with PE-conjugated anti–IL-4 mAb
and FITC-conjugated anti–IFN-
 
g
 
 for 45 min on ice. The per-
centage of cells expressing cytoplasmic IL-4 or IFN-
 
g
 
 was deter-
mined by flow cytometry (FACSCalibur™; Becton Dickinson).
 
Production of OVA Gene Transfectants.
 
A20 B lymphoma cells
were transfected with chicken OVA cDNA, which was donated
by Dr. M.J. Bevan, Research Institute of Scripps Clinic, La Jolla,
CA (29). Transfectants were designated as A20-OVA tumor
cells.
 
Cytotoxicity.
 
The cytotoxicity mediated by Th1- or Th2-
dominant cells was determined by 4-hr 
 
51
 
Cr-release assays as de-
scribed previously (30). A20 parental cells, A20-OVA cells, or
OVA
 
323–339
 
 peptide–pulsed A20 cells were used as target cells.
The cytotoxicity (as a percent) was calculated by the method de-
scribed previously (30).
 
Adoptive Tumor Immunotherapy.
 
A20-OVA cells (2 
 
3
 
 10
 
6
 
)
were intradermally inoculated into BALB/c mice. When the tu-
mor mass became palpable (6–8 mm), Th1 or Th2 cells (2 
 
3
 
 10
 
7
 
)
were intravenously transferred into the tumor-bearing mice. The
antitumor activity mediated by the transferred cells was deter-
mined by measuring changes over time of the means of two per-
pendicular diameters of the tumor mass. The mean of six mice
per group was indicated. In all experiments, tumor-free mice
were followed for 
 
.
 
90 d.
 
Results
 
OVA-specific Th1 and Th2 Cells Elicited from TCR-Tg
Mice Can React with A20-OVA Tumor Cells.
 
Th1 and Th2
cells were induced from CD4
 
1
 
CD45RB
 
1
 
 
 
naive Th cells
isolated from DO11.10 TCR-Tg mice, which recognize
OVA
 
323–339
 
 peptide (OVA-pep) bound on I-A
 
d
 
 molecules.
Th1 cells were generated from naive Th cells by culture
with OVA-pep in the presence of IL-2, IL-12, IFN-
 
g
 
, and
anti–IL-4 mAb, whereas Th2 cells were derived from naive
Th cells by culture with OVA-pep in the presence of IL-2,
IL-4, anti–IFN-
 
g
 
, and anti–IL-12 mAb. As summarized in
Fig. 1, 99% of the cells cultured under Th1 conditions for
10 d consisted of CD4
 
1
 
 
 
T cells, and 
 
z
 
70% of the cells ex-
pressed intracellular IFN-
 
g
 
 but not IL-4 (Fig. 1, A and B).
In contrast, 99% of the cells cultured under Th2 conditions
for 10 d consisted of CD4
 
1
 
 T cells, and 
 
z
 
60% of the cells
expressed intracellular IL-4 but not IFN-
 
g
 
 (Fig. 1, C and
D). To apply these OVA-specific Th1 and Th2 cells to tu-
mor immunotherapy, we generated I-A
 
d
 
–positive A20- 
619
 
Nishimura et al.
 
OVA tumor cells expressing OVA antigen by transfection
with the OVA gene. The A20-OVA tumor cells secreted
OVA protein into the culture supernatant, which was de-
tectable by ELISA (data not shown). A20-OVA cells stim-
ulated OVA-specific Th1 and Th2 cells to induce the pro-
duction of IFN-
 
g
 
 and IL-4, respectively (Fig. 1, E and F).
Moreover, Th1 cells lysed A20-OVA tumor cells, although
Th2 cells exhibited a negligible cytotoxicity (Fig. 1, G and
H). Th1 cells appeared to lyse A20-OVA tumor cells
mainly mediated by perforin, but not by TNF-
 
a
 
 and the
Fas/FasL pathway, because inhibition of granular exocyto-
sis (30) caused almost complete inhibition of the cytotoxic-
ity, whereas this blocking effect was not demonstrated by
anti–TNF-
 
a 
 
mAb plus anti-FasL mAb (data not shown). In
some cases, Th2 cells showed low but significant cytotoxic-
ity against A20-OVA, but this appeared to be derived from
the contamination of IFN-
 
g
 
–producing Th1 or Th0 cells
(data not shown), because IFN-
 
g
 
–nonproducing pure Th2
cell populations exhibited negligible cytotoxic activity (Fig.
1, F and H). The same stimulatory effect against Th1 and
Th2 cells was also demonstrated by OVA-pep–pulsed A20
tumor cells, but not untreated A20 tumor cells (Fig. 1, E–H).
These results demonstrated that the OVA peptide fragment
from A20-OVA bound to I-A
 
d
 
 and was able to stimulate
class II–restricted OVA
 
323–339
 
-specific Th1 and Th2 cells to
trigger their immunological functions.
 
Establishment of an Adoptive Tumor Immunotherapy Model
Using Antigen-specific Th Cells.
 
To determine the precise
role of Th1 and Th2 cells in antitumor immunity, we de-
signed a novel adoptive tumor immunotherapy model us-
ing OVA-specific Th1 and Th2 cells in conjunction with
A20-OVA tumor-bearing mice. Fig. 2 A shows the exper-
imental set-up for these experiments. BALB/c mice were
inoculated with 2 
 
3
 
 10
 
6
 
 A20-OVA cells, and when the tu-
mor mass became palpable (6–8 mm), 2 
 
3
 
 10
 
7
 
 Th1 or Th2
cells were transferred into the tumor-bearing mice. As
shown in Fig. 2 B, the established A20-OVA tumor mass
was completely rejected by adoptive transfer of OVA-spe-
cific Th1 cells, but not nonspecific Th1 cells, which were
induced from splenic Th cells from wild-type BALB/c
mice by activation with anti-CD3 mAb under Th1-induc-
ing conditions. However, the growth of parental A20 tu-
mor cells was not inhibited by transfer of OVA-specific
Th1 cells (Fig. 2 C). These results clearly demonstrated that
this adoptive tumor immunotherapy model allowed us to
investigate the role of antigen-specific Th cells in antitumor
immunity.
 
The Distinct Role of Th1 and Th2 Cells for Antitumor Im-
mune Responses In Vivo.
 
As shown in Fig. 3 A, both Th1
and Th2 cells exhibited strong antitumor activity in vivo
and completely eradicated the tumor mass after adoptive
transfer. All the mice cured from the tumor by Th1 or Th2
Figure 1. Characteristics of Th1 and Th2 cells from DO11.10 TCR-Tg mice and their activation by A20-OVA tumor cells. Th1 and Th2 cells were
induced from CD41CD45RB1 naive Th cells obtained from DO11.10 TCR-Tg mouse spleen cells under the conditions described in Materials and
Methods. The expression of CD4/CD8 antigen (A and C) and cytoplasmic cytokine (IL-4/IFN-g) expression (B and D) in Th1 (A and B) and Th2 cells
(C and D) was determined by flow cytometric analysis. The cytokine-producing ability of Th1 (hatched bars) and Th2 cells (black bars) was determined
by measuring the amounts of IFN-g (E) or IL-4 (F) in culture supernatants after coculture with A20 tumor cells, A20 tumor cells pulsed with OVA-pep
(A20-pep), or A20-OVA tumor cells, for 12 h. ND, not detected. The cytotoxic activity of Th1 (G) and Th2 cells (H) against A20 tumor cells (m), A20
tumor cells pulsed with OVA-pep (A20-pep) (d), or A20-OVA tumor cells (s) was measured by 4-h 51Cr-release assays. The bars represent mean 6 SE
of triplicate samples. 
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cell transfer were free of tumor for .90 d (data not
shown). These experiments were repeated .10 times, and
identical results were obtained. For the complete cure of
tumor-bearing mice, the transfer of .107 cells was required
for both Th1 and Th2 cell therapy (data not shown). Al-
though both Th1 and Th2 cells exhibited antitumor activ-
ity in vivo, totally distinct processes of tumor rejection ap-
peared to be included. The typical pattern of tumor growth
or tumor rejection in control, Th1-transferred, or Th2-
transferred mice is shown in Fig. 3 B. Interestingly, the tu-
mor mass of mice that received Th1 cells gradually changed
into a small, white mass and completely disappeared 7–10 d
after cell transfer. In contrast, in tumor-bearing mice that
received Th2 cells, the tumor mass changed to a red color
7–10 d after cell transfer, and a strong tumor necrosis was
observed. This clear difference suggested that Th1 and Th2
cells eradicate tumors using distinct immunological mecha-
nisms. To understand these distinct antitumor mechanisms,
we studied the tumor tissue by histological analysis (Fig. 4).
Although no significant lymphocyte infiltration was ob-
served in control tumor tissue (Fig. 4 A), a marked lym-
phocyte infiltration was present in tumor tissue of mice that
received Th1 cells (Fig. 4 B). However, in mice that re-
ceived Th2 cells, a marked infiltration of inflammatory cells
such as eosinophils and neutrophils was observed around
the center of the tumor mass (Fig. 4 C). These results sug-
gested that both Th1 and Th2 cells exhibited a strong anti-
tumor activity in vivo, but that these cells used distinct tu-
mor rejection mechanisms.
Tumor Rejection Mechanisms Mediated by Th1 and Th2
Cells. Fig. 5 A shows that intravenous injection of anti-
CD4 mAb, anti-CD8 mAb, or anti–IFN-g mAb com-
pletely inhibited the therapeutic effect of Th1-mediated
adoptive immunotherapy. These results demonstrated that
Th1 cells by themselves are not enough to induce complete
tumor eradication and that the interaction between Th1
cells and CD81 T cells through cytokines such as IFN-g
may be essential to induce successful tumor rejection. The
requirement for CD81 T cells in Th1-cell therapy was
confirmed by demonstrating that the therapeutic effect of
Th1 cell transfer was not induced in DO11.10 TCR-Tg
Figure 2. Establishment of an adoptive tumor immunotherapy model
using antigen-specific Th cells. (A) The protocol for adoptive tumor im-
munotherapy using OVA-specific Th1 or Th2 cells. A20-OVA tumor
cells were intradermally inoculated into wild-type BALB/c mice. When
the tumor formed a mass of 6–8 mm in diameter, 2 3 107 OVA-specific
Th1 or Th2 cells, induced from DO11.10 TCR-Tg mice, were trans-
ferred into the tumor-bearing mice. The therapeutic effect of Th1 or Th2
cell transfer was determined by measuring tumor size. According to the
above protocol (A), OVA-specific Th1 cells (OVA-Th1, d), antigen-
nonspecific 2C11-activated Th1 cells (2C11-Th1, m), or saline (None,
s) were intravenously injected into A20-OVA–bearing BALB/c mice
(B) or parental A20-bearing BALB/c mice (C). The antitumor activity of
Th1 cells was determined by measuring changes over time of the means
of two perpendicular diameters of tumor mass. Results are presented as
mean 6 SE of six mice. The tumor-free mice were followed for .90 d.
Figure 3. The distinct role of
Th1 and Th2 cells for eradication
of established tumors in vivo. (A)
OVA-specific Th1 cells (d),
OVA-specific Th2 cells (s), or
saline (m) were intravenously in-
jected into BALB/c mice bearing
A20-OVA tumors. The antitu-
mor activity of Th1 and Th2 cells
was determined by measuring
changes over time of the means
of two perpendicular diameters of
the tumor mass. Results are pre-
sented as mean 6 SE of six mice.
The tumor-free mice were fol-
lowed for .90 d. (B) Typical tu-
mor growth or regression pattern
in saline- (a), Th1- (b), or Th2-
treated mice (c). Similar results
were obtained in .10 indepen-
dent experiments. The arrow in-
dicates the site of tumor inocula-
tion in Th1-treated mice.621 Nishimura et al.
mice that have I-Ad–restricted OVA-reactive CD41 T cells,
but not CD81 T cells (Fig. 5 B). To further extend these
findings, we carried out adoptive transfer experiments us-
ing tumor-bearing RAG22/2 mice that lack T, NKT, and
B cells. A20-OVA tumors were inoculated into BALB/c
background RAG22/2 mice, and when these tumors be-
came palpable, the mice received OVA-specific Th1 or
Th2 cells. As shown in Fig. 6, the growth of A20-OVA tu-
mors in RAG22/2 mice was initially strongly inhibited by
both Th1 and Th2 cells, but the tumor cells finally grew
out in both types of mice, although regrown tumor cells
expressed OVA antigen and could stimulate cytokine pro-
duction of Th cells (data not shown). Thus, a single transfer
of Th1 or Th2 cells by itself cannot completely cure tu-
mor-bearing mice. These results strongly suggested that
OVA-reactive CD81  T cells, activated in wild-type
BALB/c mice early after tumor inoculation, play an impor-
tant role in Th1- and Th2-mediated adoptive immuno-
therapy. To further investigate the role of CD81 T cells in
Th1 and Th2 cell therapy, OVA-reactive CD81 T cells (2 3
105 cells) obtained from A20-OVA–immunized mice were
transferred into RAG22/2 mice 7 d before the experiment.
The small number (2 3 105 cells) of CD81 T cells trans-
ferred into RAG22/2 mice revealed marked expansion in
vivo, and they made up .10% of spleen cells of RAG22/2
mice 1 wk after the cell transfer (data not shown). The
transfer of CD81 T cells alone did not inhibit the growth
of A20-OVA tumor cells (Fig. 6 A). However, when A20-
OVA–bearing RAG22/2 mice first received CD81 T cells
from A20-OVA–immunized mice and then received
OVA-specific Th1 or Th2 cells, all of the mice were com-
pletely cured from the tumor. A significant but incomplete
tumor growth inhibition was also observed when un-
primed CD81 T cells were transferred into RAG22/2 mice
(Fig. 6 B). These results clearly demonstrated the critical
role for antigen-specific CD81 T cells in complete tumor
eradication induced by adoptive transfer of antigen-specific
Th1 or Th2 cells.
Figure 4. Histochemical anal-
ysis of the cellular mechanisms
underlying Th1- and Th2-medi-
ated tumor eradication in vivo.
Tumor tissues were removed from
tumor-bearing mice 7 d after
treatment with saline (A), Th1-
cell transfer (B), or Th2-cell trans-
fer (C). The tissues were stained
with hematoxylin and eosin.
Figure 5. Tumor eradication mechanisms
mediated by Th1 and Th2 cells. Th1 cell
therapy was carried out using wild-type
BALB/c mice and DO11.10 TCR-Tg mice
according to the protocol described in the
legend to Fig. 2 A. (A) At days 21 and 0
before Th1 cell transfer, either saline (s),
anti-CD4 mAb (n), anti-CD8 mAb (m),
anti–IFN-g mAb (j), or rat IgG (d) was
intravenously injected into tumor-bearing
BALB/c mice. (B) A20-OVA tumor cells
were intradermally inoculated into wild-
type BALB/c mice (s,  d) or BALB/c
background TCR-Tg mice (n, m). When
the tumor mass became palpable, Th1 cells
(d,  m) were transferred into the tumor
bearing mice. As a control, mice were
treated with saline (s, n). The antitumor
activity of Th1 cells was determined by
measuring changes over time of the means
of two perpendicular diameters of the tumor
mass. Results are presented as mean 6 SE of
six mice. The tumor-free mice were fol-
lowed for .90 d.622 The Role of Th1 and Th2 Cells in Tumor Eradication
Adoptive Tumor Immunotherapy by Th1 Cells Can Induce
Immunological Memory for CTL Generation. Next, we ex-
amined the therapeutic mechanisms of Th1 and Th2 cell
therapy in terms of acquisition of immunological memory
beneficial for CTL generation. Mice cured from tumors by
Th1 and Th2 cell therapy were rechallenged with A20-
OVA tumor cells. Fig. 7 A shows that both types of mice
rejected A20-OVA tumors, but were unable to reject syn-
geneic Meth A tumor cells (data not shown). These results
indicated that mice cured from A20-OVA tumors had ac-
quired immunological memory. However, these memory
cells, elicited after restimulation with mitomycin C–treated
A20-OVA cells, produced totally different patterns of cy-
tokines and differed in their cytotoxic potential (Fig. 7, B
and C). Spleen cells from mice cured by Th1 cell therapy
produced IFN-g and revealed high cytotoxicity against
A20-OVA but low cytotoxicity against A20 tumor cells
(Fig. 7 B). In contrast, spleen cells from mice cured by Th2
cell therapy produced high levels of IL-4 but little IFN-g
(Fig. 7 B), and had little cytotoxicity against A20-OVA
(Fig. 7 C). Thus, these findings strongly suggested that im-
munotherapy using adoptive transfer of Th1 cells appeared
to be more effective than Th2 cells for inducing immuno-
logical memory suitable for the generation of CTL re-
sponse. It was also demonstrated that some of the cured
mice from A20-OVA by Th1 cell therapy, but not by Th2
cell therapy, showed resistance against rechallenged paren-
tal A20 tumor cells (data not shown).
Figure 6. Requirement for CD81 T cells
in inducing complete elimination of trans-
planted tumors in response to Th1 or Th2
cell therapy. The tumor therapy model was
carried out according to the legend to Fig. 2
A except that aliquots (2 3 105/mouse) of
CD81 T cells from immunized mice (i-
CD8, A) or unprimed mice (ni-CD8, B)
were transferred into the mice 7 d before the
inoculation of A20-OVA tumor cells. CD81
T cells were isolated by cell sorting from
A20-OVA–immunized BALB/c mice or
untreated BALB/c mice. (A) When the tu-
mor mass became palpable, the mice were
treated with intravenous injection of saline
(A20-OVA, d), Th1 cells (m), or Th2 cells
(j). The tumor-bearing mice transferred
with CD81 T cells from tumor-immunized
mice (i-CD8) were also treated with intravenous injection of saline (s), Th1 cells (n), or Th2 cells (h). (B) When the tumor mass became palpable, the
mice were treated with intravenous injection of saline (A20-OVA, d), Th1 cells (m), or Th2 cells (j). The tumor-bearing mice transferred with CD81
T cells from unprimed mice (ni-CD8) were also treated with intravenous injection of saline (s), Th1 cells (n), or Th2 cells (h). The antitumor activity
of Th1 and Th2 cells was determined by measuring changes over time of the means of two perpendicular diameters of the tumor mass. Results are pre-
sented as mean 6 SE of six mice. The tumor-free mice were followed for .90 d.
Figure 7. Adoptive transfer of
Th1 cells but not Th2 cells in-
duces cellular immunological
memory. (A) Mice cured from
A20-OVA tumors after Th1 (d)
or Th2 cell therapy (s) were re-
challenged by intradermal injec-
tion of 2 3 106 viable A20-OVA
tumor cells. Untreated mice (m)
were used as controls. Tumor
growth was determined by mea-
suring changes over time of the
means of two perpendicular di-
ameters of the tumor mass. Re-
sults are presented as mean 6 SE
of six mice. The tumor-free mice
were followed for .90 d. (B)
Mice cured from A20-OVA tu-
mors after Th1 or Th2 cell ther-
apy were killed, and their spleen
cells were restimulated in vitro with mitomycin C–treated A20-OVA by mixed lymphocyte tumor reaction (MLTR). As control, untreated BALB/c
mice (None) were used for MLTR. After culture for 2 d, the levels of IFN-g (black bars) and IL-4 (hatched bars) in culture supernatants were measured
by ELISA. The bars represent mean 6 SE of three mice. (C) The cells were harvested from MLTR cultures from mice that had received Th1 cells (d,
s), Th2 cells (m, n), or no cells (None, j, h), and their cytotoxicity was measured using 51Cr-labeled A20-OVA (d, m, j) or A20 tumor cells (s, n,
h).The results are presented as mean 6 SE of three mice.623 Nishimura et al.
Th1 and Th2 Cells Use Distinct Cell–Cell Adhesion Interac-
tions during Eradication of Tumors In Vivo. Finally, we ex-
amined the role of distinct cell adhesion molecules in Th1
and Th2 cell therapy. While investigating the expression
and function of adhesion molecules involved in cell migra-
tion, we found that Th1 cells, in response to stimulation
with anti-CD3 mAb and phorbol ester, show strong LFA-
1/ICAM-1–dependent homotypic adhesion (28; Fig. 8 C).
However, no significant cell aggregation was observed for
similarly activated Th2 cells (Fig. 8 D). This homotypic
cell–cell aggregation was strongly blocked by anti–LFA-1
or anti–ICAM-1 mAb, but not by control rat Ig or anti–
VLA-4 mAb (data not shown). From these results, we con-
cluded that Th1 and Th2 cells have distinct capacity to use
LFA-1/ICAM-1 cell adhesion interactions. This differen-
tial ability to form homotypic cell–cell aggregates did not
result from a defect in LFA-1 or ICAM-1 expression, be-
cause both Th1 and Th2 cells expressed high levels of
LFA-1 and ICAM-1 at the cell surface (Fig. 5, A and B).
To investigate whether LFA-1/ICAM-1 interactions are
important for the induction of antitumor activity in vivo,
we examined the effect of anti–LFA-1 mAb administration
on Th1 and Th2 cell therapy. Mice were inoculated with
A20-OVA tumor cells, and when tumors became palpable,
mice were treated by intravenous injection of anti–LFA-1
mAb (500 mg/mouse) twice at days 21 and 0 before adop-
tive transfer of Th1 or Th2 cells. As shown in Fig. 5 E, the
therapeutic ability of Th1 cells was completely abrogated
by anti–LFA-1 mAb administration. However, no signifi-
cant inhibitory effect by anti–LFA-1 mAb was observed for
Th2-mediated antitumor activity (Fig. 5 F). These results
indicated that Th1 and Th2 cells showed distinct require-
ments for LFA-1–dependent cell–cell interactions in vitro
and in vivo: LFA-1–dependent cell migration appeared to
be critical for Th1-cell therapy but not for Th2-cell therapy.
Discussion
Several lines of evidence have indirectly demonstrated a
role for the Th1/Th2 balance in antitumor immunity.
First, the cytokine IL-12, which stimulates Th1-dominant
immunity in vivo, was shown to have strong in vivo anti-
tumor activity against a variety of tumors, including pri-
mary tumors (18, 19, 31, 32). Second, in vivo neutraliza-
tion of IFN-g caused the inhibition of the antitumor effect
of IL-12, suggesting that IFN-g–producing Th1 cells may
play an important role in tumor rejection. However, this
Figure 8. Th1 and Th2 cells use distinct cell adhesion interactions during eradication of tumors in vivo. (A) Expression of LFA-1 antigen on Th1 and
Th2 cells. (B) Expression of ICAM-1 on Th1 and Th2 cells. Dotted line, unstained control cells. (C and D) LFA-1/ICAM-1–dependent homotypic cell–
cell aggregation. Th1 (C) and Th2 cells (D) (2 3 106 cells) were stimulated with 20 ng/ml of PMA. After culture for 1 h, homotypic aggregates were
formed. Typical cell–cell aggregates were photographed. We confirmed that the homotypic aggregation was strongly blocked by addition of either anti–
LFA-1 mAb or anti–ICAM-1 mAb (data not shown). (E and F) The effect of anti–LFA-1 mAb administration in vivo on the therapeutic ability of Th1
(E) or Th2 cells (F) was examined using the protocol described in the legend to Fig. 2 A. (E) When the A20-OVA tumor mass became palpable, the mice
were treated with saline (s), Th1 cell transfer (d), or Th1 cell transfer after anti–LFA-1 mAb administration (n). (F) When the A20-OVA tumor mass
became palpable, the mice were treated with saline (s), Th2 cell transfer (d), or Th2 cell transfer after anti–LFA-1 mAb administration (n). The anti–
LFA-1 mAb (500 mg/mouse) was intravenously injected into the mice at days 21 and 0 before cell transfer. The antitumor activity of Th1 and Th2 cells
was determined by measuring changes over time of the means of two perpendicular diameters of the tumor mass. Results are presented as mean 6 SE of six
mice. The tumor-free mice were followed for .90 d.624 The Role of Th1 and Th2 Cells in Tumor Eradication
conclusion is weakened by the observation that other T
cells, including NKT cells and CD81 T cells, can produce
IFN-g in response to IL-12, and that these cell types can
activate Th1-dominant immunity (33, 34). Indeed, it was
recently demonstrated that the antitumor activities of IL-12
are mediated, in large part, by NKT cells (34). Moreover,
the finding that Th2-derived cytokines (IL-4, IL-5, IL-6,
IL-10) show antitumor activities in vivo that are as strong
as the antitumor activities of Th1 cytokines (20–23, 35) has
made it difficult to conclude which cell type is the most ef-
fective for eliciting complete tumor regression in vivo.
To address this issue, we designed a new adoptive tumor
immunotherapy model using tumor antigen–specific Th1
or Th2 cells. As tumor cells, we used OVA gene–trans-
fected tumor cells, and Th1 and Th2 cells were induced
from mice transgenic for an OVA-specific TCR. Our re-
sults demonstrated that both Th1 and Th2 cells show po-
tent antitumor activities in vivo (Fig. 3). Interestingly, Th1
cells induced a marked lymphocyte infiltration into the tu-
mor mass and eradicated the tumor mass via cellular immu-
nity. In sharp contrast, Th2 cells induced inflammatory re-
sponses at the tumor site and induced tumor necrosis (Fig.
4). The finding that Th2 cells, which can produce high
levels of IL-4, induced the inflammation characterized by
eosinophils and neutrophils is consistent with previous re-
sults with IL-4 gene–transfected tumors, which were re-
jected by inflammatory cells that included eosinophils and
neutrophils (22, 36). However, it remains unclear how
Th2 cells induce tumor necrosis.
Another important difference between Th1 and Th2 cell
therapy is that Th1 therapy was able to induce a strong im-
munological memory suitable for the generation of CTLs,
whereas Th2 cells did not induce the immunological mem-
ory for CTL generation very well (Fig. 7). Some of the
cured mice from A20-OVA by Th1 cell therapy but not
Th2 cell therapy showed resistance against rechallenged pa-
rental A20 tumor cells (data not shown), indicating that
Th1 cell therapy might also be beneficial for the generation
of CTLs, which recognize unknown tumor-rejection anti-
gen expressed on parental A20 tumor. Based on our obser-
vation that in vivo administration of anti-CD4 mAb, anti-
CD8 mAb, or anti–IFN-g mAb blocked the therapeutic
effect of Th1 cells against tumors (Fig. 5 A), we suggest that
transferred Th1 cells migrate into local tumor sites, produce
IFN-g, and facilitate the induction of antitumor CD81
CTLs in vivo. The requirement for CD81 T cells in Th1
cell therapy is also demonstrated by our finding that
DO11.10 TCR-Tg mice that have OVA-reactive CD41 T
cells, but not CD81 T cells, were unable to permanently
clear the tumor by Th1 cell therapy (Fig. 5 B). Direct evi-
dence for the requirement for CD81 T cells was demon-
strated using adoptive transfer of CD81 T cells into
RAG22/2 mice (Fig. 6). This experiment also indicated
that NKT cells are not involved in Th1- and Th2-induced
antitumor activity in vivo because NKT cells are not differ-
entiated in RAG22/2 mice, which are deficient in NKT
cells, mainstream T cells, and B cells. Th2 cells contained
,2% of IFN-g–producing cells (Fig. 1 D), which might
exhibit negligible cytotoxicity against A20-OVA (Fig. 1
H). Indeed, in some cases, Th2 cells exhibited low but sig-
nificant cytotoxicity against A20-OVA in parallel with the
increased production of IFN-g. However, even in such
cases, the IFN-g produced by contaminating cells (Th1 or
Th2) appeared not to be involved in the triggering of anti-
tumor activity of Th2 cells, because administration of anti–
IFN-g mAb caused no significant blocking of the Th2-
mediated therapeutic effect (data not shown). In mice that
were cured from A20-OVA tumors by Th2 therapy, A20-
OVA–specific CTLs were not detected. These findings
suggest that antigen-nonspecific CD81 killer T cells are in-
volved in Th2-mediated adoptive immunotherapy. Alter-
natively, CD81 TC2 cells (33) induced by IL-4 may con-
tribute to tumor eradication in Th2 cell therapy. Since the
immunological memory in mice cured by Th2 cell transfer
may be mediated by humoral immunity, we are currently
investigating whether Th2 immunological memory can be
transferred into normal mice by serum isolated from tu-
mor-cured mice.
The distinct antitumor immunity mediated by Th1 and
Th2 cells may be due to the distinct cell adhesion interactions
involved in the migration of these cells into tumor tissues
across endothelia. Consistent with previous results (37), we
found that Th1 cells express higher levels of P-selectin
ligands and produced higher amounts of chemokines com-
pared with Th2 cells (data not shown). In addition, we found
that Th1 cells exhibit strong LFA-1/ICAM-1–dependent
cell–cell interactions (Fig. 8 C), which are critical for lym-
phocyte activation, cell-mediated cytotoxicity, and trans-
migration of lymphocytes into inflammatory tissues (38,
39). In contrast, Th2 cells were defective in LFA-1/
ICAM-1–mediated cell–cell interactions (Fig. 8 D), but
were able to interact with the extracellular matrix on en-
dothelia through the integrin aVb3 (data not shown).
These results suggest that Th1 cells express adhesion mole-
cules that facilitate transmigration into tumor tissues across
the tumor vessels. Indeed, antitumor therapeutic activity of
Th1 cells was completely blocked by administration of
anti–LFA-1 mAb, whereas the activities of Th2 cells were
not affected by anti–LFA-1 mAb injection (Fig. 8, E and
F). From these results, we speculate that, at the tumor local
site, Th1 cells actively respond to tumor cells and produce
cytokines, which recruit other effector cells such as CD81
T cells, NKT, or NK cells into the tumor tissue. In con-
trast, Th2 cells, which are unable to enter tumor tissue be-
cause of a defect of adhesion mechanisms, may accumulate
on the endothelial cells around the tumor mass and induce
tumor necrosis via molecules such as TNF-a that damage
tumor vessels (40). However, we have recently demon-
strated that in vivo administration of anti–IL-4, anti–IL-10,
or anti–TNF-a was unable to block the tumor necrosis in-
duced by Th2 cell therapy (data not shown). Therefore,
unknown mechanisms appear to be involved in Th2-induced
tumor necrosis. One possibility would be that Th2-derived
cytokines activated other inflammatory cells and the prod-
ucts of these cells damage endothelial cells to induce tumor
necrosis. This hypothesis is strongly supported by recent625 Nishimura et al.
findings by Hung et al. (41) that CD41 T cells play an im-
portant role in inducing antitumor activity in vivo through
activation of eosinophils and macrophages that produce su-
peroxide and nitric oxide.
The finding that transfer of .107 Th1 or Th2 cells with
CD81 T cells is required for the complete rejection of
tumor (data not shown) means that, at an early phase of
tumor rejection, the bursting of a strong cytokine storm
derived from Th1 or Th2 cells may be essential for over-
coming a strong suppression in the tumor-bearing host and
for induction of CD81 CTL–mediated antitumor protec-
tive immunity in tumor-bearing mice. The present data
demonstrate that Th1 and Th2 cells use distinct tumor
eradication mechanisms. However, based on the following
considerations, Th1 cells may be more suitable for adoptive
tumor immunotherapy in the future: (a) Th1 cell therapy,
but not Th2 cell therapy, induces strong immunological
memory beneficial for CTL generation (Fig. 7); (b) Th2
cells produce high levels of IL-6, which can contribute to
cachexia in late stage tumor-bearing hosts (42); and (c) in
our experience, IFN-g–producing Th1 cells are easily ex-
panded from total spleen or peripheral blood cell popula-
tions, while it is hard to induce pure Th2 cells producing
IL-4 but not IFN-g from total spleen or peripheral blood
cells in humans and mice (data not shown). In a previous
report (43), we demonstrated that culture of tumor-infil-
trating lymphocytes (TILs) with IL-2 plus IL-12 results in a
profound increase in the development of autologous tu-
mor-reactive CTLs. Moreover, we showed that this proto-
col enhanced the generation of autologous tumor-reactive
Th1-dominant cells (our unpublished data). Therefore, if
we can develop a large scale culture system for the genera-
tion of autologous tumor-reactive Th1 cells from TILs or
PBLs of tumor patients, the adoptive tumor immunother-
apy using tumor-specific Th1-dominant cells may be possi-
ble. The cytokine IL-12 shows great promise for the devel-
opment of tumor immunotherapy (18, 19, 31, 32). However,
recent findings have demonstrated that IL-12 also has ad-
verse effects owing to overstimulation of Th1-dominant
immunity (44). In terms of side effects, adoptive transfer of
in vitro IL-12–activated Th1-dominant cells may minimize
side effects, and could make the management of side effects
easier. Thus far, IL-12 has been suggested for cytokine
therapy and gene therapy of cancer. This paper further in-
dicates that IL-12 may be a useful tool for application to a
novel tumor immunotherapy protocol using the adoptive
transfer of Th1-dominant T cells and/or CTLs (Th1
helper/killer therapy).
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